Vimarsana
Biggest News Aggregation in the World

Page 9 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Compugen Ltd. (NASDAQ:CGEN) Receives $8.33 Average Target Price from Brokerages - Vimarsana News

Compugen Ltd. (NASDAQ:CGEN) Receives $8.33 Average Target Price from Brokerages

Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokers […]

These Israeli pharmaceutical stocks are down in the wake of Hamas attack - Vimarsana News

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical giant Teva are down Monday following Hamas's attack over the weekend.

Compugen to Present at Single Cell Genomics 2023 Meeting - Vimarsana News

Compugen to Present at Single Cell Genomics 2023 Meeting

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Compugen Gets Patent In Japan For Combination Of Anti-PVRIG, TIGIT, PD-1 Antibody To Treat Cancer - Vimarsana News

Compugen Gets Patent In Japan For Combination Of Anti-PVRIG, TIGIT, PD-1 Antibody To Treat Cancer

(RTTNews) - Compugen Ltd. (CGEN) announced the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple combination ...

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer - Vimarsana News

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

HOLON, Israel, Oct. 2,  2023 /PRNewswire/ -- Compugen Ltd.  a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese...